NexImmune, Inc. announced that Kristi Jones has been appointed as the Company's member of its Board of Directors. Her appointment follows the departure of Scott Carmer, who submitted his letter of resignation this week. Prior to her roles as Chief Business Officer and Chief Operating Officer at NexImmune, Ms. Jones spent more than 25 years in various strategic and operational leadership roles at AstraZeneca (and its biologics R&D subsidiary, MedImmune), Genentech and Eli Lilly. At AstraZeneca, she was Vice President of Portfolio Strategy and Management, where she played an instrumental role in building a scientifically innovative, diverse portfolio creating new value for the Company.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
3.475 USD | +1.02% | -3.06% | +57.21% |
Apr. 17 | North American Morning Briefing : Stock Futures -2- | DJ |
Apr. 16 | NexImmune, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
1st Jan change | Capi. | |
---|---|---|
+57.21% | 4.72M | |
+8.86% | 114B | |
+11.51% | 104B | |
-12.55% | 22.41B | |
-1.05% | 22.28B | |
-5.29% | 19.07B | |
-38.29% | 18B | |
-3.10% | 17.89B | |
+7.82% | 14.28B | |
+35.85% | 12.55B |
- Stock Market
- Equities
- NEXI Stock
- News NexImmune, Inc.
- NexImmune, Inc. Announces Management Changes